Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Targeting the DNA Replication Stress Response in Pancreatic Cancer
EF 2018-19
Résumé
Pancreatic cancer is among the highest mortality cancers in Canada, with a prognosis that has remained unchanged for many decades. This is in part due to the inadequacy of reliable methods for early detection of the cancer, but more notably due to the lack of effective treatment against advanced stage disease. Gemcitabine is currently the leading treatment for patients with pancreatic cancer and functions by targeting the critical process of DNA replication in cancer cells, resulting in cell death. However, resistance to gemcitabine treatments is either naturally present within cells or rapidly acquired in cells that were initially sensitive, with little improvement found in current gemcitabine combination therapies. Hence, to develop effective combination treatments, it is critical to identify which cellular factors are responsible for modulating gemcitabine sensitivity in pancreatic cancer cells. With recent advances in genetic screening technology, we are now able to see the individual effects of deleting each gene from the human genome, a task that was unachievable before. In my project, I have taken advantage of this technology to identify the full complement of genes that, when deleted, increase sensitivity or resistance to gemcitabine in different pancreatic cancer cell lines. I am now focusing on determining the cellular mechanisms by which some of these genes modulate gemcitabine sensitivity. My work will provide the first exhaustive list of genes that modulate gemcitabine response in pancreatic cancer cells, as well as great insight into the molecular basis of the sensitivity and resistance of pancreatic cancers to therapy, both of which are essential for the development of new pancreatic cancer treatments.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
408189
Name
Ubhi Tajinder
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting the DNA Replication Stress Response in Pancreatic Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Combination Therapy; Crispr-Cas9; Dna Replication Stress; Functional Genomics; Gemcitabine; Genome-Wide Screening; Mechanisms Of Resistance; Pancreatic Ductal Adenocarcinoma
Abstract
Pancreatic cancer is among the highest mortality cancers in Canada, with a prognosis that has remained unchanged for many decades. This is in part due to the inadequacy of reliable methods for early detection of the cancer, but more notably due to the lack of effective treatment against advanced stage disease. Gemcitabine is currently the leading treatment for patients with pancreatic cancer and functions by targeting the critical process of DNA replication in cancer cells, resulting in cell death. However, resistance to gemcitabine treatments is either naturally present within cells or rapidly acquired in cells that were initially sensitive, with little improvement found in current gemcitabine combination therapies. Hence, to develop effective combination treatments, it is critical to identify which cellular factors are responsible for modulating gemcitabine sensitivity in pancreatic cancer cells. With recent advances in genetic screening technology, we are now able to see the individual effects of deleting each gene from the human genome, a task that was unachievable before. In my project, I have taken advantage of this technology to identify the full complement of genes that, when deleted, increase sensitivity or resistance to gemcitabine in different pancreatic cancer cell lines. I am now focusing on determining the cellular mechanisms by which some of these genes modulate gemcitabine sensitivity. My work will provide the first exhaustive list of genes that modulate gemcitabine response in pancreatic cancer cells, as well as great insight into the molecular basis of the sensitivity and resistance of pancreatic cancers to therapy, both of which are essential for the development of new pancreatic cancer treatments.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ubhi, Tajinder
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~